摘要
目的探讨钙黏蛋白表达与表皮生长因子受体(EGFR)分子靶向治疗敏感或耐药的相关性。方法乳腺癌细胞(MCF-7和MDA-MB-231)、膀胱癌细胞株(T24)、子宫颈鳞癌细胞(SiHa)、大细胞肺癌细胞株(H460)、肝癌细胞株(SK-HEP-1和MHCC97-H)以及单核细胞白血病(THP-1)等8种细胞分别用表皮生长因子受体酪胺酸激酶抑制药(EGFR-TKI)PD153035和吉非替尼处理48 h,采用噻唑蓝(MTT)法检测其敏感或耐药性,计算各细胞的半数抑制浓度(IC50),并与各细胞钙黏蛋白水平比较,观察相关性。结果随着PD153035和吉非替尼浓度的升高,MCF-7、MDA-MB-231、T24及SiHa细胞生存率明显下降,表现为敏感,钙黏蛋白表达阳性;H460、SK-HEP-1、MHCC97-H及THP-1细胞生存率未见明显下降,表现为耐药,钙黏蛋白表达阴性。结论 EGFR-TKI对上皮性肿瘤细胞的生存率与钙黏蛋白的表达水平存在相关性;钙黏蛋白可能在调节EGFR分子靶向治疗的敏感性方面起重要作用;钙黏蛋白作为标志物为临床筛选合适的患者进行EGFR-TKI分子靶向治疗提供了重要线索。
Objective To explore the correlation of E-cadherin expression and the sensitivity to EGFR-TKI molecular targeted therapy. Methods Eight kinds of cells,MCF-7,MDA-MB-231,T24,SiHa,H460,SK-HEP-1,MHCC97-H and THP-1 were treated with EGFR-TKI PD153035 and gefitinib,respectively,for 48 hours. The drug-sensitivity was detected by MTT,and the IC50 of cells were calculated. The E-cadherin protein were detected and compared. Results Followed with PD153035 and gefitinib treatment,the survival rates of MCF-7,MDA-MB-231,T24 and SiHa significantly reduced,and more E-cadherin protein expressed. However, the survival rates of the H460, SK-HEP-1, MHCC97-H, and THP-1 cells showed opposite results. Conclusion The sensitivity of epithelial cancer cells to EGFR-TKI is correlated with E-cadherin expression. E-cadherin may play a significant role on regulateing the sensitivity to EGFR-TKI molecular targeted therapy. E-cadherin is a key biomarker for recruiting appropriate patients for EGFR-TKI molecular targeted therapy.
出处
《医药导报》
CAS
北大核心
2014年第5期582-585,共4页
Herald of Medicine
关键词
钙黏蛋白
表皮生长因子受体酪胺酸激酶抑制药
耐药
靶向治疗
E-cadherin
Epidermal growth factor receptor-tyrosine kinase inhibitors
Resistance
Targeted therapy
作者简介
作者简介邢荣春（1985-），男，湖北黄冈人，住院医师，硕士，专业方向：主要从事普通外科肿瘤研究。电话：（0）13469870373，E—mail：xingrongchun@sina．com。
通讯作者郑军（1965-），男，湖北宜昌人，主任医师，教授，研究方向：主要从事普通外科肿瘤研究。电话：（0）15871598533，E—mail：zhengjun1995@163．com。
